What did @selenaalexisss actually say?
Straight answer: the transcript contains no medical claims about GLP-1 medications, tirzepatide, or weight loss. The video caption references GLP-1 use and excitement about upcoming weight loss, but the spoken audio is song lyrics, not health information.
The creator's caption reads "Did my happy dance at the end because I know ima lose some more pounds this week" and tags a platform called Freya, using hashtags like #glp1forweightloss and #tirzepatide. That context tells us this is a GLP-1 journey video. But the transcript itself, word for word, is a music track. There are no spoken claims about dosing, efficacy, side effects, or medication comparisons to evaluate.
This is worth being precise about. Fact-checking a song played over a weight loss video is not the same as fact-checking health advice. The caption's emotional framing, "I know ima lose some more pounds this week," is personal enthusiasm, not a medical claim.
Does the science back this up?
There is solid evidence that GLP-1 receptor agonists like tirzepatide produce meaningful weight loss, but the creator didn't actually make a scientific claim here, so this is context, not a correction.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown strong clinical results. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found participants on the highest dose (15 mg weekly) lost a mean of 20.9% of body weight over 72 weeks. That is genuinely significant data. The SURMOUNT-2 trial extended similar findings to people with type 2 diabetes.
The general sentiment that tirzepatide works for weight loss in the right clinical context? That's supported. But the creator didn't cite a mechanism, make a dosing claim, or compare tirzepatide to other drugs. They danced to a song. The science is relevant background, not a verdict on what was said.
What did they get wrong (or right)?
Nothing was technically wrong because nothing was technically claimed. But the broader content pattern here deserves scrutiny even if this specific video dodges it.
GLP-1 content on TikTok, broadly, has a documented accuracy problem. A 2023 analysis of social media GLP-1 content found that a significant proportion of popular posts contained misleading dosing information or unsupported claims about weight loss timelines. This video doesn't do that. The caption is emotional and personal, which is legitimate. Sharing a journey is different from giving medical advice.
One thing worth flagging: the Freya tag suggests this is branded or affiliate content for a telehealth platform. If creators are compensated to post GLP-1 journey content, the FTC requires disclosure. There is no visible #ad or #sponsored tag in the provided hashtags. That is a compliance gap worth noting, even if it is not a medical accuracy issue.
What should you actually know?
If you are considering GLP-1 therapy because of videos like this one, here is what the evidence actually says, without the happy dance.
Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It requires a prescription and medical supervision. Compounded versions of tirzepatide exist, but they are not FDA-approved and are not equivalent to brand-name Zepbound. Do not treat them as interchangeable.
- Weight loss results vary significantly. The SURMOUNT-1 trial showed a range, not a guaranteed outcome.
- Side effects, primarily nausea, vomiting, and gastrointestinal issues, affect a meaningful portion of users and can lead to discontinuation.
- Weight often returns after stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
- These medications work best alongside dietary changes and are not a standalone fix.
Watching someone's weight loss journey on TikTok can be motivating. It is not a substitute for a clinical evaluation.